National Reference Laboratory (NRL), part of M42, has partnered with Qritive to deploy advanced artificial intelligence-powered prostate cancer diagnostics in the UAE, marking a significant step in the digital transformation of pathology services.
The new technology is designed to support faster, more accurate, and more consistent prostate cancer detection and diagnosis, reinforcing NRL’s efforts to integrate advanced technologies into clinical care. At the center of the deployment is Qritive’s AI Prostate module, which digitally analyzes tissue samples, identifies areas of concern, and provides structured insights to support cancer detection and grading.
Integrated into NRL’s diagnostic workflow at Cleveland Clinic Abu Dhabi, the platform is expected to help pathologists identify subtle disease patterns, standardize interpretation, improve workflow efficiency, and accelerate clinical decision-making for cancer patients.
The AI solution is designed to assist in detecting malignant glands, identifying tumor architecture, and enabling standardized grading in line with internationally recognized International Society of Urological Pathology (ISUP) criteria.
It can also support the characterization of Gleason patterns, quantify tumor burden, and highlight suspicious regions on digital pathology slides, providing an additional analytical layer during case reviews.
The deployment reflects the growing role of artificial intelligence in pathology and healthcare diagnostics, as medical institutions increasingly adopt digital technologies to improve diagnostic accuracy, consistency, and operational efficiency.
NRL said the collaboration supports its broader commitment to advancing precision diagnostics and enhancing patient care through innovation across the UAE healthcare sector.
Dr. Laila Abdel Wareth CEO of Diagnostics – M42
“AI is not replacing pathologists; it is strengthening their ability to make complex clinical decisions with greater confidence and efficiency. At NRL, we see AI as a transformative force in pathology, one that can enhance diagnostic precision, reduce variability, and empower our specialists to focus on the most complex clinical decisions. In diseases such as prostate cancer, where grading accuracy directly influences treatment pathways, technologies such as those developed by Qritive hold tremendous promise.”
Dr. Shweta Narang, Executive Director Medical and Commercial Operations at NRL, said that, “By bringing AI-enabled prostate diagnostics into routine practice, we are helping healthcare providers manage rising demand more efficiently, while giving patients and clinicians greater clarity at a critical stage of the care journey. This milestone reflects our commitment to advancing diagnostics and improving patient outcomes across the UAE.”
